EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models
العنوان: | EGF‑IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models |
---|---|
المؤلفون: | Yue Qiu, Zeng Qi, Zhaohui Wang, Yu Cao, Ling Lu, Huiping Zhang, David Mathes, Elizabeth Pomfret, Shi-Long Lu, Zhirui Wang |
المصدر: | Oncology Reports. 49 |
بيانات النشر: | Spandidos Publications, 2022. |
سنة النشر: | 2022 |
مصطلحات موضوعية: | ErbB Receptors, Mice, Cancer Research, Oncology, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Cell Line, Tumor, Tumor Microenvironment, Humans, Animals, Interleukin-2, Diphtheria Toxin, General Medicine |
الوصف: | The epidermal growth factor receptor (EGFR) remains one of the best molecules for developing targeted therapy for multiple human malignancies, including head and neck squamous cell carcinoma (HNSCC). Small molecule inhibitors or antibodies targeting EGFR have been extensively developed in recent decades. Immunotoxin (IT)‑based therapy, which combines cell surface binding ligands or antibodies with a peptide toxin, represents another cancer treatment option. A total of 3 diphtheria toxin (DT)‑based fusion toxins that target human EGFR‑monovalent EGFR IT (mono‑EGF‑IT), bivalent EGFR IT (bi‑EGF‑IT), and a bispecific IT targeting both EGFR and interleukin‑2 receptor (bis‑EGF/IL2‑IT) were recently generated by the authors. Improved efficacy and reduced toxicity of bi‑EGF‑IT compared with mono‑EGF‑IT in immunocompromised HNSCC mouse models was reported. In the present study, bis‑EGF/IL2‑IT were generated using a unique DT‑resistant yeast expression system and evaluated the |
تدمد: | 1791-2431 1021-335X |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::899b36b26f4487f8f4cc8d6b40d23444Test https://doi.org/10.3892/or.2022.8474Test |
رقم الانضمام: | edsair.doi.dedup.....899b36b26f4487f8f4cc8d6b40d23444 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 17912431 1021335X |
---|